UCLA: Attacking metastatic prostate cancer early with combination treatment improves outcomes

Cortechs.ai, EDAP TMS announce OnQ prostate-assisted robotic HIFU procedure

Cortechs.ai and EDAP TMS SA announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco Prostate Center.

February 14, 2025

Vol.51 No.06

In Brief

UCLA awarded $1.72M NIH grant to train brain cancer scientists

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from NIH to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.

Inherited WNT9B mutation linked to increased prostate cancer risk, study finds

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study published in JCO Precision Oncology.

Wistar researchers identify target to overcome treatment-resistant melanoma

The lab of The Wistar Institute’s Jessie Villanueva has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper at the journal Science Translational Medicine.